Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Goserelin Acetate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    51 result(s) found for: Goserelin Acetate. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2006-004587-30 Sponsor Protocol Number: GOS/002/C Start Date*: 2006-11-04
    Sponsor Name:NOVOSIS AG
    Full Title: An open label, parallel group, Phase III clinical study in patients with advanced prostate cancer suitable for hormonal manipulation to demonstrate the non-inferiority of a new three-month Novosis ...
    Medical condition: prostate cancer suitable for hormonal manipulation
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001931-36 Sponsor Protocol Number: CLEE011E2301 Start Date*: 2014-12-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the t...
    Medical condition: premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) DE (Completed) BE (Completed) IT (Completed) PT (Completed) PL (Completed) BG (Completed) ES (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2014-002484-15 Sponsor Protocol Number: AMW/004/C Start Date*: 2015-12-14
    Sponsor Name:AMW GmbH
    Full Title: An open label, multiple dose, Phase III clinical study in patients with prostate cancer to investigate the clinical efficacy of AMW goserelin 3.6 mg implant in its application system
    Medical condition: prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-006975-41 Sponsor Protocol Number: URONCOR06-24 Start Date*: 2022-07-27
    Sponsor Name:GICOR
    Full Title: Short versus long-term androgen deprivation therapy combined with salvage radiotherapy in prostate cancer patients with biochemical recurrence after prostatectomy: a multicentre phase III randomise...
    Medical condition: Short versus long-term androgen deprivation therapy combined with salvage radiotherapy in prostate cancer patients with biochemical recurrence after prostatectomy
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002556-24 Sponsor Protocol Number: CLEE011XDE01 Start Date*: 2016-10-14
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A national phase IIIb, multi-center, open label study for women and men with hormone-receptor positive, HER2-negative locally advanced or metastatic breast cancer treated with ribociclib (LEE011) i...
    Medical condition: HR+, HER2- advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000593-32 Sponsor Protocol Number: MIT-Zo002-C301 Start Date*: 2019-06-25
    Sponsor Name:Novalon S.A.
    Full Title: Phase III, open-label, multi-center study to assess the pharmacodynamic (PD), pharmacokinetic (PK) and safety of Zoreline 10.8 mg goserelin subcutaneous implant (Novalon) in male subjects with pros...
    Medical condition: Prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-004351-29 Sponsor Protocol Number: 2008-02-IMP-5 Start Date*: 2008-12-18
    Sponsor Name:HEXAL AG
    Full Title: OPEN LABEL, MULTICENTER STUDY ON PHARMACOKINETICS, PHARMACODYNAMICS, EFFICACY AND SAFETY OF GOSERELIN 10.8 mg IMPLANT HEXAL IN PATIENTS WITH ADVANCED HORMONE DEPENDENT PROSTATE CANCER
    Medical condition: Palliative treatment of advanced hormone dependent prostate cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-005276-27 Sponsor Protocol Number: FE 200486 CS35 Start Date*: 2009-07-17
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: An Open-Label, Multi-Centre, Randomised, Parallel-Arm One-Year Trial, Comparing the Efficacy and Safety of Degarelix Three-Month Dosing Regimen with Goserelin Acetate in Patients with Prostate Canc...
    Medical condition: prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: HU (Completed) NL (Completed) DE (Completed) FI (Completed) CZ (Completed) GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004001-29 Sponsor Protocol Number: D8664C00008 Start Date*: 2006-02-15
    Sponsor Name:AstraZeneca AB
    Full Title: An Open Label, Randomised, Parallel Group, Multicentre Study to Compare ZOLADEX™ 10.8 mg Given Every 12 Weeks with ZOLADEX 3.6 mg Given Every 4 Weeks in Pre-menopausal Women with Oestrogen Receptor...
    Medical condition: Oestrogen receptor (ER) positive advanced breast cancer (ABC) in pre-menopausal women
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-000066-18 Sponsor Protocol Number: S65935 Start Date*: 2022-03-23
    Sponsor Name:Universitaire Ziekenhuizen Leuven
    Full Title: Metastasis-directed therapy for oligorecurrent prostate cancer: a randomized phase III trial
    Medical condition: Oligorecurrent hormone-sensitive prostate cancer patients
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-020825-42 Sponsor Protocol Number: RTOG0815 Start Date*: 2010-11-08
    Sponsor Name:Radiation Therapy Oncology Group
    Full Title: A PHASE III PROSPECTIVE RANDOMIZED TRIAL OF DOSE-ESCALATED RADIOTHERAPY WITH OR WITHOUT SHORT-TERM ANDROGEN DEPRIVATION THERAPY FOR PATIENTS WITH INTERMEDIATE-RISK PROSTATE CANCER
    Medical condition: intermediate risk prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    12.1 10026389 Malignant neoplasm of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000799-14 Sponsor Protocol Number: 0080CA002 Start Date*: 2015-01-16
    Sponsor Name:Novalon S. A.
    Full Title: Phase III, open-label, multi-center study to assess the pharmacodynamic (PD), pharmacokinetic (PK) and safety of Zoreline 10.8 mg goserelin subcutaneous implant (Novalon) in male patients with pros...
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-000273-39 Sponsor Protocol Number: Start Date*: 2015-07-13
    Sponsor Name:Belfast Health and Social Care Trust
    Full Title: Neo-adjuvant Androgen Deprivation Therapy, Pelvic Radiotherapy and RADium-223 for new presentation T1-4 N0/1 M1B adenocarcinoma of prostate (ADRRAD Trial)
    Medical condition: Metastatic castration sensitive prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2016-004586-67 Sponsor Protocol Number: CBYL719X2402 Start Date*: 2017-07-13
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A phase II, multicenter, open-label, two-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (...
    Medical condition: Hormone receptor positive, HER2-negative advanced breast cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) BE (Completed) NL (Completed) DK (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-004365-13 Sponsor Protocol Number: CTOR18001GZA Start Date*: 2019-02-04
    Sponsor Name:GZA vzw
    Full Title: A phase II randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy (ADT) with LHRH agonist or antagonist versus anti-adrogen therapy...
    Medical condition: Prostate cancer patients with biochemical progression after radical prostatectomy and planned for salvage radiotherapy
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-015122-11 Sponsor Protocol Number: GBG54 Start Date*: 2012-08-27
    Sponsor Name:GBG Forschungs GmbH
    Full Title: A prospective, randomised multi-centre phase II study evaluating the adjuvant, neoadjuvant or palliative treatment with tamoxifen +/- GnRH analogue versus aromatase inhibitor + GnRH analogue in m...
    Medical condition: Breast Cancer in Male Patients
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061020 Breast cancer male PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002893-11 Sponsor Protocol Number: PASIPHAE Start Date*: 2017-08-14
    Sponsor Name:Karolinska University Hospital
    Full Title: A phase 2, international, multicenter, open-labeled, randomized trial of PAlbociclib and fulvestrant vs. Standard oral capecitabine In Patients with Hormone receptor positive/HER2 negative Advanced...
    Medical condition: Hormone receptor positive/HER2 negative advanced breast cancer with endocrine resistance
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Prematurely Ended) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-004334-17 Sponsor Protocol Number: EORTC-1532-GUCG Start Date*: 2017-09-21
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: A phase 2 Randomized Open-Label Study of Oral darolutamide (ODM-201) vs. androgen deprivation therapy (ADT) with LHRH agonists or antagonist in Men with Hormone Naive Prostate Cancer
    Medical condition: Hormone Naive Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10071119 Hormone-dependent prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BE (Trial now transitioned) AT (Completed) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000154-19 Sponsor Protocol Number: UC-0105/1701 Start Date*: 2017-07-19
    Sponsor Name:UNICANCER
    Full Title: A phase II randomized trial comparing alpelisib and fulvestrant versus chemotherapy as maintenance therapy in patients with PIK3CA mutated advanced breast cancer
    Medical condition: PIK3CA mutated, HR+/Her2- metastatic breast cancer who do not present progressive disease after 6-8 cycles of 1st or second line chemotherapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001030-33 Sponsor Protocol Number: MRCPR09 Start Date*: 2005-11-23
    Sponsor Name:University College London
    Full Title: PATCH Prostate Adenocarcinoma: TransCutaneous Hormones A randomised-controlled trial of transcutaneous oestrogen patches versus LHRH agonists in prostate cancer.
    Medical condition: Newly diagnosed or relapsing patients with locally advanced or metastatic prostate cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 03 06:13:50 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA